Daily Bulletin

The Times Real Estate

.

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Chromatin Bioscience Signs Collaboration Agreement with Astellas

EDINBURGH, Scotland, April 14, 2025 /PRNewswire/ -- Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, is pleased to announce a collaboration agreement with Astellas Pharma, a global life sciences company.

Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to design cell-selective synthetic promoters aligned with Astellas' target profile. The designed promoters are expected to enable highly precise and durable gene expression in specific cell types.

"We're excited to begin this collaboration with Astellas," said Michael Roberts, CEO and Founder of Chromatin Bioscience. "We believe the ability to precisely control targeted gene expression is becoming increasingly critical across diverse applications in biotechnology. This collaboration reflects the growing interest in synthetic promoter technology as a key enabler in the development of precision-targeted biological systems."

Chromatin Bioscience's chromatinLENS platform enables the identification of gene regulatory elements from the dark genome and the rational design of synthetic promoters tailored to specific applications. The platform can be applied across a range of sectors—including therapeutics, agritech, industrial biotechnology, and bioprocessing. The collaboration with Astellas further validates the potential of the chromatinLENS platform and represents the latest milestone in a series of collaborations that are shaping Chromatin's continued growth and impact.

For more information about Chromatin Bio's recent collaborations, visit https://www.chromatinbio.com/news

Notes to Editors

About Chromatin BioscienceChromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for targeted gene control systems. Its proprietary platform enables precise, cell-type-selective, and durable gene expression, which is key to advancing the next generation of therapeutics, bioproduction systems and agritech innovations. Chromatin's synthetic promoters have been integral to a growing number of client programs. For more information, visit www.chromatinbio.com.

 

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/4659283_AE59283_0

Business News

Sydney Pipe Relining: The Smarter Way to Restore Infrastructure

In large-scale construction and civil works, outdated or damaged pipelines can bring operations to a halt. At Revolution Pipe Relining, we understand that time is money—especially for remedial build...

Daily Bulletin - avatar Daily Bulletin

Teleperformance (TP) Business Insights Report Reveals Key Shifts in Consumer Behaviour

TP’s Business Insights report  into consumer behaviors and preferences, taking in more than 57,000 respondents across 19 sectors, is shedding new light on how evolving channel preferences are resh...

Daily Bulletin - avatar Daily Bulletin

Navigating the Ascent: Your Strategic Guide to Executive Job Search

The air at the executive level is different. The stakes are higher, the competition more intense, and the path to your next leadership role requires a nuanced and strategic approach. Unlike more jun...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals